Author(s)

Makoto Shiraishi, Kensuke Shinohara, Masashi Akamatsu, Yasuhiro Hasegawa

Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki-City, Japan.

Purpose: To clarify the impact of bone metabolism disorder on lumbago in Parkinson’s Disease (PD). Methods: Data was retrospectively analyzed from 52 patients with PD in our outpatient clinic for more than 1 year (mean age, 63 ± 4 years old; mean duration from onset, 6.3 ± 0.8 years). Patients’ characteristics, comorbid musculoskeletal disorders, serum bone metabolism biomarkers, and bone mineral density were examined. Results: Twenty-one PD patients (40.2%) had chronic lumbago. Severe comptocormia and scoliosis were the most common musculosketal disorders in this group (47.6%) affected by lumbago, followed by osteoporosis (14.3%), compression fracture (4.8%). There was no significant difference in the duration of PD, body mass index, frequency of falls, bone mineral density, tartrate-resistant acid phosphatase-5b, osteocalcin, and N-terminal telopeptide between PD patients with or without chronic lumbago. Multivaritae logistic regression analysis identified the independent predictors of chroni lumbago in PD patients as Hoen-Yahr stage (odds ration [OR] = 2.794, 95%CI 1.103 - 7.076), and elevated serum 1,25-OH₂ vitamin D level ([OR] = 0.92, 95%CI 0.86 - 98). Conclusion: Bone metabolism disorders are found to be associated with chronic lumbago in PD patients.

Chronic Lumbago, Parkinson’s Disease, Bone Mineral Metabolism, 1, 25-(OH)₂-Vitamin D

Shiraishi, M. , Shinohara, K. , Akamatsu, M. and Hasegawa, Y. (2016) Contribution of Musculoskeletal Disorders to Chronic Lumbago in Parkinson’s Disease. Advances in Parkinson's Disease, 5, 61-66. doi: 10.4236/apd.2016.53008.